Zilberberg Marya D, Shorr Andrew F, Micek Scott T, Mody Samir H, Kollef Marin H
School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA.
Washington Hospital Center, Washington, DC.
Chest. 2008 Nov;134(5):963-968. doi: 10.1378/chest.08-0842. Epub 2008 Jul 18.
Patients with health-care-associated pneumonia (HCAP) are frequently infected with a resistant pathogen and receive inappropriate empiric antibiotics (ie, pathogens resistant to administered treatment). Initial inappropriate treatment has been shown to increase hospital mortality. It is not known whether escalation in response to culture results mitigates this risk.
We identified patients admitted with a culture-positive pneumonia between January 2003 and December 2005. HCAP patients met one or more of the following criteria indicating ongoing contact with the health-care system: recent hospitalization (< or = 12 months), admission from a nursing home, immunosuppression, or long-term dialysis. We compared survivors to nonsurvivors among those patients with HCAP still hospitalized beyond 48 h.
Of 431 HCAP patients, 396 patients (92%) were alive and still hospitalized beyond 48 h. The crude mortality rate was 21.5%. Compared to survivors, nonsurvivors were significantly more likely to be treated with inappropriate empiric antibiotics (37.6% vs 24.1%, p = 0.013). Although mortality was higher among patients receiving inappropriate than appropriate therapy (30.0% vs 18.3%, p = 0.013), this difference was more pronounced among nonbacteremic patients (odds ratio [OR], 2.45; 95% confidence interval [CI], 1.26 to 4.75) than bacteremic patients (OR, 1.25; 95% CI, 0.41 to 3.57). In a logistic regression, inappropriate empiric antibiotic treatment among nonbacteremic patients was independently associated with mortality (OR, 2.88; 95% CI, 1.46 to 5.67); treatment escalation did not attenuate the risk of death.
Among HCAP patients alive and hospitalized beyond 48 h, hospital mortality was high and, in the absence of bacteremia, greater with initial inappropriate antibiotic treatment. Despite subsequent escalation, initial inappropriate antibiotic choice nearly tripled the risk of hospital death.
医疗保健相关肺炎(HCAP)患者常感染耐药病原体并接受不恰当的经验性抗生素治疗(即病原体对所使用的治疗药物耐药)。已证实初始不恰当治疗会增加医院死亡率。目前尚不清楚根据培养结果调整治疗是否能降低这种风险。
我们确定了2003年1月至2005年12月期间因培养阳性肺炎入院的患者。HCAP患者符合一项或多项以下表明持续接触医疗保健系统的标准:近期住院(≤12个月)、从疗养院入院、免疫抑制或长期透析。我们比较了HCAP患者中仍住院超过48小时的幸存者和非幸存者。
在431例HCAP患者中,396例(92%)存活且仍住院超过48小时。粗死亡率为21.5%。与幸存者相比,非幸存者接受不恰当经验性抗生素治疗的可能性显著更高(37.6%对24.1%,p = 0.013)。尽管接受不恰当治疗的患者死亡率高于接受恰当治疗的患者(30.0%对18.3%,p = 0.013),但这种差异在非菌血症患者中(优势比[OR],2.45;95%置信区间[CI],1.26至4.75)比菌血症患者中(OR,1.25;95%CI,0.41至3.57)更为明显。在逻辑回归分析中,非菌血症患者接受不恰当经验性抗生素治疗与死亡率独立相关(OR,2.88;95%CI,1.46至5.67);调整治疗并未降低死亡风险。
在存活且住院超过48小时的HCAP患者中,医院死亡率很高,且在无菌血症的情况下,初始不恰当抗生素治疗的死亡率更高。尽管随后进行了调整,但初始不恰当的抗生素选择使医院死亡风险增加了近两倍。